What Research Use Only Labeling Does for a Merchant Account

Research-use-only labeling does not make a sale legal, and it does not settle whether a processor will board you. Under federal rules, what a product is meant for is judged from the whole offer, which includes your advertising, your product pages, and the circumstances of how you sell. That is the single most expensive misunderstanding in this category. Sellers buy a disclaimer expecting a shield, then find that neither the FDA nor a payment reviewer treats it as one.

Key takeaways

• “Intended use” is judged objectively, from your statements, your product’s design, and the circumstances of distribution. One line of label text is evidence, not a verdict.
• The FDA has quoted sellers’ own research-use disclaimers back at them and still said the products were meant as drugs for people (FDA warning letters, December 2024 and March 2026).
• Research-shaped wording is not the same as research intent. Copy about preclinical studies and the scientific community appeared in a letter as evidence of human-drug intent.
• What the labeling posture does change is whether your file is reviewable. A consistent store can be underwritten. A contradictory one gets declined without anyone explaining why.

What does research use only labeling actually do?

Research-use-only labeling, usually shortened to RUO, is a statement that a product is sold for laboratory research and not for people. It does real work. It sets the terms of the offer, it tells buyers what they are getting, and it is one of the first things a payment underwriter looks for on a peptide store.

What it does not do is decide anything on its own. It is one input into a judgment that gets made from everything else on your site. Treating it as a switch that clears you is how sellers end up surprised twice, first by a regulator and later by a processor.

This post is about payment risk, not about whether your specific products are lawful to sell. That question turns on your compounds, your marketing, and your facts, and it belongs with your own counsel. What follows is how the labeling question gets read by the people deciding whether you keep a merchant account.

How does the FDA decide what a product is intended for?

The rule is short and it is worth reading once. Under 21 CFR 201.128, intended use means “the objective intent of the persons legally responsible for the labeling of an article.” Objective is the operative word. It is not what you meant privately. It is what a reasonable outside reader would conclude from what you did.

The rule then lists the evidence. Intent may be shown by your expressions, by the design or composition of the product, or by the circumstances surrounding its distribution. It gives examples, including labeling claims, advertising, and oral or written statements by you or your representatives. The current version of the rule dates from a 2021 final rule (86 FR 41401).

Read that list again and notice what is missing. There is no clause that lets one statement override the others. A disclaimer is an expression, so it goes into the pile with everything else you said and did. If your dosing chart, your product description, and your checkout flow all point one way, a line of small print pointing the other way does not cancel them out.

What the FDA’s own warning letters say about the disclaimer

This is not a theory about how the rule might be applied. The FDA writes it out plainly in letters that anyone can read.

In a December 2024 letter to a seller of GLP-1 weight-loss compounds, among them semaglutide, retatrutide and tirzepatide, the agency wrote that despite statements marketing the products as “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY,” evidence from the websites established that the products were intended to be drugs for human use. The FDA quoted the disclaimer, acknowledged it, and moved past it in the same sentence.

A March 2026 letter to a different seller, this one offering retatrutide, tirzepatide and bacteriostatic water, used the same construction. The agency noted the site’s “Research Use Only” statement and its “not intended for human consumption, medical use, or veterinary use” wording, then said the website still established human drug intent. In both cases the products were called unapproved new drugs, which means drugs sold without the FDA approval that federal law requires.

Both letters happened to involve GLP-1 weight-loss compounds, and that is worth saying out loud. GLP-1s sit in a harder and separate regulatory position from research peptides generally, so a seller in that lane starts from a worse place than an ordinary research-supply catalog. The intended-use reasoning is not compound-specific, though. It turns on what the whole offer says the product is for, which is why the same analysis reaches any store selling under a research-use label.

Here is the part that should change how you write product pages. In the December 2024 letter, the copy the FDA quoted as evidence was itself research-flavored. One product page described a compound as “designed specifically for the scientific community to advance research in metabolic disorders.” That same page listed “Research Applications” and described the compound as “extensively utilized in preclinical studies.” The seller was writing in a research register. It did not help, because the claims underneath that register described effects on human bodies.

Research-shaped wording is not the same thing as research intent. Sprinkling the words study, research, and investigational over benefit claims does not convert them. It just makes the contradiction easier to spot.

The clause most sellers have never read

There is one more line in the rule, and it is the one that catches people who think they have cleaned up their site.

Objective intent may also be shown by circumstances in which the product is, with the seller’s knowledge, offered or used for a purpose it is neither labeled nor advertised for. In plain words, what you know about how buyers actually use the product is part of the evidence. You do not have to say it for it to count.

That is why the surrounding details of a store matter so much. The March 2026 letter treated a seller’s bacteriostatic water, a sterile liquid used to mix injectable products, as a drug in its own right. The reasoning was that offering it alongside injectable peptides showed the two were meant to be used together. Nothing on the water’s own page had to say so.

Payment reviewers reach the same conclusion by a shorter route. They are not applying the regulation. They are looking at a catalog and asking who realistically buys this. Injection supplies, single-vial quantities, subscription reorders, and a support inbox full of dosing questions all answer that question before your disclaimer gets a chance to.

What the labeling posture actually changes for your account

None of this means RUO framing is pointless. It means you should be clear about which job it does.

It does not decide legality. It does not protect you from a regulator. What it decides is whether your account is reviewable. An underwriter reading a peptide file is trying to work out how likely this business is to become a problem, and consistency is the strongest signal available. A store where the labeling, the product copy, the age gate, the checkout attestation, and the documentation all say the same thing can be priced. A store where they contradict each other cannot, so the safe answer is no.

That is the difference between the two outcomes in this category. Sellers with a coherent posture get underwritten on purpose, with the compliance questions settled before terms are set. Sellers with a contradictory one get approved by a light signup screen and closed later, which is the pattern behind why processors decline peptide sellers in the first place.

What the published processor policies say about labeling

The policies themselves show how much the labeling turns the decision, once you read the exact words.

Stripe’s nearest entry does not prohibit research chemicals. It prohibits “Incorrectly labeled research chemicals,” which makes the labeling the condition rather than the category. Adyen names peptides and research chemicals directly and splits them by who is buying. Business-to-business sales sit in a restricted tier that needs extra documentation. The same products sold direct to consumers are prohibited outright. Wise is the plainest of the group and bans “Anabolic steroids and peptides” without conditions.

Two of those three turn on something you control. Whether your labeling is correct, and whether you are selling to research buyers or to consumers, are the exact questions your site answers on every page. You can read the verbatim policy text for each of these in our prohibited businesses lookup.

This is also where a peptide store differs from a supplement brand. A supplement is openly sold for people to take, and its risk sits in the health claims and the chargeback profile. A research compound claims not to be for people at all, so its whole account rests on whether the store behaves as if that is true.

Where the 2026 compounding news fits

Peptides were in the federal news through 2026, and none of it changes the labeling question.

The activity concerned which substances licensed pharmacies may use when compounding medicines for patients with prescriptions. An FDA advisory committee voted in July 2026 to recommend adding several peptides to that list. A recommendation is not a decision. The FDA has not adopted it, rulemaking after a vote like that can take more than a year, and it says nothing about selling research compounds through an online store. Citing it in a merchant application will not help your case, and the detail sits in the cluster’s overview of processor declines.

Getting the posture right before you apply

Read your own site the way a stranger would, because that is the only reading that counts.

Start with the product pages, since that is where the evidence lives. Pull anything describing effects on a human body, any dosing or injection instruction, and any before-and-after imagery. Then look at the parts that speak without words. Check what you sell alongside the compounds, what quantities you offer, and what your support inbox is actually answering. Move the research-use acknowledgment out of the footer and into checkout, where a buyer has to engage with it. Keep your documentation together so a reviewer has something to weigh in your favor.

Then apply somewhere that underwrites this category deliberately. Our peptide payment processing page covers what that review looks at and what to have ready. The labeling questions get settled at the start, instead of surfacing as an account closure months later.